You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic

  • Authors: Sara M. Tolaney, MD, MPH; Elizabeth A. Mittendorf, MD, PhD; Javier Cortés, MD, PhD; Hope S. Rugo, MD
  • CME / ABIM MOC Released: 11/28/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/28/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for hematology and oncology specialists, surgeons, obstetricians, and gynecologists.

The goal of this activity is for the learner to be better able to approach challenging cases in the clinic when making decisions regarding adjuvant therapy for patients with HR-positive, HER2-negative early breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current recommendations for assessing risk of recurrence in patients with HR-positive, HER2-negative early breast cancer (EBC)
  • Have greater competence related to
    • Determining eligibility of patients for adjuvant treatment with a cyclin-dependent kinase (CDK) 4/6 inhibitor
  • Demonstrate greater confidence in their ability to
    • Address challenges in determining the eligibility of patients for adjuvant treatment with a CDK 4/6 inhibitor


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Sara M. Tolaney, MD, MPH

    Associate Professor of Medicine
    Harvard Medical School
    Associate Director, Susan F. Smith Center for Women's Cancers
    Director, Clinical Trials, Breast Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts, United States

    Disclosures

    Sara M. Tolaney, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: ARC Therapeutics; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol Myers Squibb; Certara; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech/Roche; Gilead; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec Medical Inc.; OncXerna; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen Inc.; Silverback Therapeutics; Zentalis; Zymeworks; 4D Pharma
    Research funding from: AstraZeneca; Bristol Myers Squibb; Cyclacel; Eisai; Exelixis; Genentech/Roche; Gilead; Lilly; Merck; NanoString Technologies; Nektar Therapeutics; Novartis; Odonate Therapeutics; Pfizer; Sanofi; Seagen Inc.

  • Elizabeth A. Mittendorf, MD, PhD

    Professor of Surgery
    Harvard Medical School
    Rob and Karen Hale Distinguished Chair in Surgical Oncology
    Dana-Farber Brigham Cancer Center
    Boston, Massachusetts, United States

    Disclosures

    Elizabeth A. Mittendorf, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; Exact Sciences; Merck; Roche/Genentech
    Research funding from: Roche/Genentech

  • Javier Cortés, MD, PhD

    Head, International Breast Cancer Center (IBCC)
    Medica Scientia Innovation Research (MedSIR)
    Barcelona, Spain

    Disclosures

    Javier Cortes, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Athenex; Bioasis; BioInvent; Boehringer Ingelheim; Celgene; Cellestia; Clovis Oncology; Daiichi Sankyo; Ellipses; Erytech; Gilead; GEMoaB; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Roche; Seagen Inc.; Zymeworks
    Speaker or member of speakers bureau for: Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung Bioepis
    Research funding from: Ariad Pharmaceuticals; AstraZeneca; Bayer Healthcare; Baxalta GmbH/Servier Affaires; Eisai; F. Hoffmann-La Roche; Guardant Health; Merck Sharp & Dohme; Pfizer; PIQUR Therapeutics; Puma C; Roche
    Stock options from: Nektar Therapeutics

  • Hope S. Rugo, MD

    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California San Francisco
    Comprehensive Cancer Center
    San Francisco, California, United States

    Disclosures

    Hope S. Rugo, MD, has the following relevant financial relationships:
    Research funding from: AstraZeneca; Ayala; Boehringer Ingelheim; Daiichi Sankyo; Gilead; Lilly; MacroGenics; Merck; Novartis; Pfizer; Polyphor; Roche; Seagen Inc.; Sermonix
    Other: Honoraria from: Mylan; Napo Pharmaceuticals; Puma; Samsung

Editors

  • Victoria Phoenix, BS

    Medical Education Director, Medscape, LLC

    Disclosures

    Victoria Phoenix, BS, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic

Authors: Sara M. Tolaney, MD, MPH; Elizabeth A. Mittendorf, MD, PhD; Javier Cortés, MD, PhD; Hope S. Rugo, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/28/2022

Valid for credit through: 11/28/2023, 11:59 PM EST

processing....

Transcrição em português

Download the pdf.

 

« Return to: Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic
  • Print